rs3093059 — CRP -757T>C

CRP Promoter Variant — A Genetic Dial for Baseline Inflammation

C-reactive protein (CRP) is the liver's first responder to inflammatory signals. Under normal conditions it circulates at low concentrations, but during acute infection or tissue injury it can surge more than 1,000-fold within hours. What's less appreciated is that baseline CRP — the level you carry when healthy — is strongly heritable, with genetic factors explaining 30–40% of variation¹¹ genetic factors explaining 30–40% of variation
Twin and family studies estimate heritability of basal CRP at 30–40%. The rs3093059 variant sits directly in the CRP gene promoter and is one of the most functionally validated of all CRP genetic regulators.

The Mechanism

rs3093059 is located approximately 757 base pairs upstream of the CRP transcription start site (papers describe it as −757T>C; on the genomic plus strand the alleles are A and G, with G being the CRP-elevating variant). This position falls within a functional E-box element (E-box 3) in the promoter. E-boxes are short DNA sequences (CANNTG) that recruit basic helix-loop-helix transcription factors such as USF1 and USF2; these factors are major drivers of CRP gene expression in hepatocytes.

Danik et al. demonstrated directly in promoter constructs that rs3093059 disrupts transcription factor binding within E-box 3, altering transcriptional activity and producing measurable differences in baseline serum CRP²² Danik et al. demonstrated directly in promoter constructs that rs3093059 disrupts transcription factor binding within E-box 3, altering transcriptional activity and producing measurable differences in baseline serum CRP
Functional study with promoter reporter assays confirming E-box disruption (PMID 15778807). The G allele strengthens E-box binding affinity, increasing basal CRP expression. This is a cis-acting effect — the variant acts on the same chromosome's CRP gene — and accounts for up to 1.14% of variance in hsCRP concentrations³³ up to 1.14% of variance in hsCRP concentrations
Contribution to hsCRP variance across multiple cohorts, comparable in magnitude to the more frequently cited rs1205 3′ UTR variant.

The Evidence

The CRP-elevating effect of rs3093059 is among the most consistently replicated findings in inflammation genetics.

Crawford et al. conducted a comprehensive survey of CRP promoter variation in European American and African American adults, finding rs3093059 among the SNPs most strongly associated with plasma CRP levels across large cardiovascular cohorts⁴⁴ Crawford et al. conducted a comprehensive survey of CRP promoter variation in European American and African American adults, finding rs3093059 among the SNPs most strongly associated with plasma CRP levels across large cardiovascular cohorts
Multi-cohort association study (PMID 15897982). In the NHLBI Family Heart Study, rs3093059 was significantly associated with CRP (P = 0.0004), and the association replicated in the Women's Health Study, the Pravastatin Inflammation/CRP Evaluation trial, and the Physicians' Health Study.

In a prospective Shanghai cohort of 2,000 unrelated Han Chinese adults, the minor G allele of rs3093059 was significantly associated with elevated circulating CRP (P < 0.001) and with incident essential hypertension (OR per CRP quartile 1.64; 95% CI 1.18–2.26)⁵⁵ the minor G allele of rs3093059 was significantly associated with elevated circulating CRP (P < 0.001) and with incident essential hypertension (OR per CRP quartile 1.64; 95% CI 1.18–2.26)
908 hypertensives, 1,092 normotensives with 2-year follow-up (PMID 22763479). This links genetically elevated CRP, via rs3093059, to downstream vascular risk.

In a large elderly Chinese cohort (RuLAS, n=1,723), rs3093059 was significantly associated with serum CRP levels (β = 0.222, P < 0.001)⁶⁶ rs3093059 was significantly associated with serum CRP levels (β = 0.222, P < 0.001)
Rugao Longevity and Ageing Study (PMID 27016573), with CRP levels increasing in a dose-dependent fashion with G allele count.

For cardiovascular outcomes, a meta-analysis of 9 case-control studies (2,992 MI patients, 4,711 controls) found rs3093059 associated with decreased MI risk, especially in Asian populations⁷⁷ meta-analysis of 9 case-control studies (2,992 MI patients, 4,711 controls) found rs3093059 associated with decreased MI risk, especially in Asian populations
Zhu et al. meta-analysis (PMID 24010569). This apparent paradox — a CRP-raising allele associated with lower MI risk in some populations — reflects the complexity of CRP's role as both biomarker and potentially active participant in vascular biology, as well as linkage disequilibrium with other CRP haplotype variants that have protective effects.

For stroke, a prospective Han Chinese cohort found rs3093059 independently predicted poor 3-month outcome after first-ever large-artery atherosclerotic ischemic stroke (dominant model OR 2.49; 95% CI 1.55–4.00; recessive model OR 3.67; 95% CI 1.22–11.03)⁸⁸ rs3093059 independently predicted poor 3-month outcome after first-ever large-artery atherosclerotic ischemic stroke (dominant model OR 2.49; 95% CI 1.55–4.00; recessive model OR 3.67; 95% CI 1.22–11.03)
Nanjing Stroke Registry (PMID 29556980).

A haplotype analysis in Chinese Han subjects (730 T2DM cases, 765 controls) found that the CGCA haplotype — which includes the A (reference/non-risk) allele at rs3093059 — was associated with decreased type 2 diabetes risk (OR 0.83; 95% CI 0.68–0.98; P = 0.047)⁹⁹ haplotype analysis in Chinese Han subjects (730 T2DM cases, 765 controls) found that the CGCA haplotype — which includes the A (reference/non-risk) allele at rs3093059 — was associated with decreased type 2 diabetes risk (OR 0.83; 95% CI 0.68–0.98; P = 0.047)
Haplotype analysis (PMID 38833006), further illustrating how this CRP locus sits at the intersection of inflammation, metabolic disease, and cardiovascular risk.

Practical Implications

Elevated basal CRP independently predicts all-cause mortality, cardiovascular events, and stroke risk across multiple population studies. The rs3093059 G allele contributes to constitutively higher CRP by increasing hepatic CRP gene transcription. This matters most when combined with environmental factors (obesity, poor diet, smoking, sedentary lifestyle) that further amplify inflammatory load.

Because CRP is a modifiable biomarker, G allele carriers have both an elevated baseline and actionable targets. High-sensitivity CRP (hs-CRP) testing provides a direct readout of how much your environment is amplifying your genetic set point: values below 1 mg/L indicate low cardiovascular inflammatory risk, 1–3 mg/L moderate risk, and above 3 mg/L high risk. Omega-3 fatty acids (EPA/DHA) reduce hs-CRP by 0.3–0.5 mg/L on average across RCTs; statins lower CRP independently of LDL by 15–25%; and weight loss produces approximately 0.13 mg/L reduction per kilogram lost.

Interactions

rs3093059 exists in strong linkage disequilibrium with three other CRP gene variants — rs1205, rs1800947, and rs2794521 — which together define major CRP expression haplotypes. The CGCA haplotype (rs1205-C, rs1130864-G, rs2794521-C, rs3093059-A) is associated with decreased type 2 diabetes risk, suggesting that haplotype context can modify the metabolic consequences of any single CRP variant. A user carrying rs3093059 AG or GG should also review their rs1205 and rs1800947 results to understand their full CRP haplotype.

The rs3093059 effect on stroke outcome (PMID 29556980) was significant after adjusting for baseline CRP, blood pressure, and other covariates, suggesting it may have effects beyond simply raising CRP — possibly through local promoter regulation affecting CRP's acute-phase response dynamics during cerebrovascular events.